Post-translational modifications of protein biopharmaceuticals

Gary Walsh

doi:10.1016/j.drudis.2010.06.009

Post-translational modifications of protein biopharmaceuticals

Gary Walsh

Department of Chemical Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

The majority of therapeutic proteins display one or more post-translational modifications (PTMs). These modifications normally influence the biochemical and therapeutic properties of such proteins. Choosing an expression system capable of generating an appropriate product PTM profile remains one of the most crucial decisions a drug developer must make. This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.

Original language	English
Pages (from-to)	773-780
Number of pages	8
Journal	Drug Discovery Today
Volume	15
Issue number	17-18
DOIs	https://doi.org/10.1016/j.drudis.2010.06.009 https://doi.org/10.1016/j.drudis.2010.06.009
Publication status	Published - Sep 2010

Access to Document

Cite this

@article{14d5de6d16444293a34fdc044228d0c4,

title = "Post-translational modifications of protein biopharmaceuticals",

abstract = "The majority of therapeutic proteins display one or more post-translational modifications (PTMs). These modifications normally influence the biochemical and therapeutic properties of such proteins. Choosing an expression system capable of generating an appropriate product PTM profile remains one of the most crucial decisions a drug developer must make. This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.",

author = "Gary Walsh",

year = "2010",

month = sep,

doi = "10.1016/j.drudis.2010.06.009",

language = "English",

volume = "15",

pages = "773--780",

journal = "Drug Discovery Today",

issn = "1359-6446",

number = "17-18",

}

TY - JOUR

T1 - Post-translational modifications of protein biopharmaceuticals

AU - Walsh, Gary

PY - 2010/9

Y1 - 2010/9

N2 - The majority of therapeutic proteins display one or more post-translational modifications (PTMs). These modifications normally influence the biochemical and therapeutic properties of such proteins. Choosing an expression system capable of generating an appropriate product PTM profile remains one of the most crucial decisions a drug developer must make. This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.

AB - The majority of therapeutic proteins display one or more post-translational modifications (PTMs). These modifications normally influence the biochemical and therapeutic properties of such proteins. Choosing an expression system capable of generating an appropriate product PTM profile remains one of the most crucial decisions a drug developer must make. This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.

UR - http://www.scopus.com/inward/record.url?scp=77956458110&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2010.06.009

DO - 10.1016/j.drudis.2010.06.009

M3 - Review article

C2 - 20599624

AN - SCOPUS:77956458110

SN - 1359-6446

VL - 15

SP - 773

EP - 780

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 17-18

ER -

Post-translational modifications of protein biopharmaceuticals

Abstract

Access to Document

Other files and links

Fingerprint

Cite this